Fondazione IRCCS Istituto Nazionale dei Tumori-ko ikertzaileekin lankidetzan egindako argitalpenak (24)

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

  2. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis

    ESMO Open, Vol. 9, Núm. 3

  3. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

    European Journal of Nuclear Medicine and Molecular Imaging

2023

  1. Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)

    Pediatric Research

  2. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  3. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

    The oncologist, Vol. 28, Núm. 1, pp. 23-32

2022

  1. Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group

    Pediatric Research, Vol. 91, Núm. 5, pp. 1069-1077

  2. Rethinking breast cancer follow-up based on individual risk and recurrence management

    Cancer Treatment Reviews, Vol. 109

2021

  1. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871

  2. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2 -Negative Advanced Breast Cancer: A Randomized Clinical Trial

    JAMA Oncology, Vol. 7, Núm. 12, pp. 1791-1799

  3. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  4. Nobody dares stopping clinical research, not even COVID-19

    npj Breast Cancer

2020

  1. Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

    Frontiers in Oncology, Vol. 10

  2. Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y)

    Breast Cancer Research

  3. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

    ESMO Open, Vol. 5

  4. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019

    European Journal of Cancer, Vol. 135, pp. 62-65

  5. Trastuzumab emtansine plus non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (Thelma): A single-arm, multicenter, phase Ib trial

    Cancers, Vol. 12, Núm. 12, pp. 1-14

2019

  1. NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

    Breast Cancer Research, Vol. 21, Núm. 1

2016

  1. Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

    Oncotarget, Vol. 7, Núm. 42, pp. 67956-67965

2013

  1. D. Torrejon, J. Cortes, D. Serpico, S. Di Cosimo à l'article de F. Vasseur et al.: KI67 chez les patientes jeunes présentant un cancer du sein. Gynecol Obstet Fertil 2013; 41(1):16-9

    Gynecologie Obstetrique et Fertilite